MarginsXMarginsX
Home › Markets › Health Care › NNNN

Anbio Biotechnology (NNNN)

NNNN trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.88
+1.57% on the day
Market cap
$558.3M
Small cap
Revenue · 2025
$8.6M
+5.6% on 2024
Net income · 2025
$6.4M
74.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1982708/000118518526001294/0001185185-26-001294-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNNNN on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryGermany
IPO year2025
SEC CIK0001982708
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inCayman Islands

Financials · 2025

LineValue
Revenue$8.6M
Net income$6.4M
Operating income$5.8M
Net margin74.1%
Operating margin66.7%
Revenue growth+5.6%
Cash$7.8M
Total assets$30.2M
P/E (computed)87.2×
P/S (computed)64.6×

Warning signs

Cash runway
13.8 months
$7.8M cash at December 31, 2025
Share count, 1 year
+1.1%
2024-12-31 to 2025-12-31
Going-concern doubt
No
20-F filed April 7, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-07
Cash and burn$7.8M cash; operating cash flow -$1.7M a quarter.Report 2025-12-31
Shares outstanding143,891,200 (2025-12-31); 142,291,200 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-07-09
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGGF CPA LTD, Guangzhou, ChinaPCAOB Form AP 2026-05-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$8.6M$6.4M-$6.7M$7.8MNo debt tags$8.6M20-F 2026-04-07
FY 2024
2024-12-31
$8.2M$2.4M$2.1M$11.8MNo debt tags$8.2M20-F 2026-04-07
FY 2023
2023-12-31
$6.7M$2.3M$898K$9.7MNo debt tags$6.7M20-F 2026-04-07
FY 2022
2022-12-31
$23.5M$10.0M$4.4M$7.1MNo debt tags$23.5M20-F 2025-04-28

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B42025-02-19
Latest annual report
FORM 20-F
20-F2026-04-07
Latest quarterly / interim
FORM 6-K
6-K2026-05-19

Source: SEC EDGAR submissions feed, 43 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.8%
1 month-10.3%
3 months-62.8%
Year to date-87.3%
1 year-83.6%
From 52-week high-90.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
MYGNMyriad Genetics Inc.$5.57-1.59%$534.3M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M
QUITAchieve Life Sciences Inc. Common Shares$6.06-4.11%$666.8M
QDELQuidelOrtho Corporation$10.21-4.93%$700.5M
NTLAIntellia Therapeutics Inc.$9.86+1.65%$1.4B
CLDXCelldex Therapeutics Inc.$28.59-0.83%$2.2B
NEOGNeogen Corporation$10.88-3.12%$2.4B
ICCCImmuCell Corporation$11.42+6.23%$103.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier